Savara Pharmaceuticals logo

Savara Pharmaceuticals

Savara Pharmaceuticals focuses on the development of an inhaled antibiotic for autoimmune pulmonary alveolar proteinosis (aPAP).

3

Funding Rounds

$16.3m

Money raised

Overview

Savara Pharmaceuticals focuses on the development of an inhaled antibiotic for autoimmune pulmonary alveolar proteinosis (aPAP).

Funding

Funding series

Funding Series Analysis

The company Savara Pharmaceuticals has raised a total of $7.73m in funding over 3 rounds.

Key Insights:

  • Savara Pharmaceuticals Series B round: $6.9m
  • Savara Pharmaceuticals Series A round: $833k
  • Savara Pharmaceuticals Series B round March 2013: $8.6m
Savara Pharmaceuticals logo
Savara Pharmaceuticals Series B round $6.9m
Savara Pharmaceuticals logo
Savara Pharmaceuticals Series A round $833k
Savara Pharmaceuticals logo
Savara Pharmaceuticals Series B round March 2013 $8.6m

Industries

Savara Pharmaceuticals is active in the following industries: